The effect of direct to consumer television advertising on the timing of treatment

Economic Inquiry

Volumn 48, Issue 2, 2010, Pages 306-322

  Bradford, W David ^a   Kleit, Andrew N ^b   Nietert, Paul J ^c   Ornstein, Steven ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952750488     PISSN: 00952583     EISSN: 14657295     Source Type: Journal    
DOI: 10.1111/j.1465-7295.2009.00215.x     Document Type: Article

References (35)

1. Arnott R, Lewis F. " The Transition of Land to Urban Use." Journal of Political Economy 1979, 87:161-69.
2. Benninga S, Helmantel M, Sarig O. " The Timing of Initial Public Offerings." Journal of Financial Economics 2005, 75:115-32.
3. Bradford W D, Kleit A, Neitert P, Mcilwain T, Ornstein S. " The Effect of Direct to Consumer Television Advertising on Physician Prescribing Behavior for the Treatment of Osteoarthritis." Health Affairs 2006, 25(5):1371-77.
4. Calfee J, Winston C, Stempski R. " Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs." Journal of Law and Economics 2002, 45(2, pt 2):673-690.
5. Capozza D, Li Y. " The Intensity and Timing of Investment: The Case of Land." American Economic Review 1994, 84:889-904.
6. Capozza D, Li Y. " Optimal Land Development Decisions." Journal of Urban Economics 2002, 51:123-42.
7. Cutler D. " The Incidence of Adverse Medical Outcomes Under Prospective Payment." Econometrica 1995, 63:29-50.
8. Donohue J, Cevasco M, Rosenthal M. " A Decade of Direct to Consumer Advertising of Prescription Drugs." New England Journal of Medicine 2007, 357:673-80.
9. Dubois R. " Pharmaceutical Promotion: Don't Throw the Baby Out with the Bath Water." Health Affairs Web Exclusive 2003, W3:96-103.
10. Hamilton B H, and V H. " Estimating Surgical Volume-Outcome Relationships Applying Survival Models: Accounting for Frailty and Hospital Fixed Effects." Health Economics 1997, 6:383-95.
11. Heckman J, Singer B. " A Method for Minimizing the Impact of Distributional Assumptions in Econometric Models for Duration Data." Econometrica 1984, 52:271-320.
12. Hurwitz M, Caves R. " Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals." Journal of Law and Economics 1988, 31:299-320.
13. Kalbfleisch J, Prentice R. " Estimation of the Average Hazard Ratio." Biometrika 1981, 68:105-112.
14. Keith A. " Regulating Information About Aspirin and the Prevention of Heart Attack." American Economic Review 1995, 85:96-99.
15. King C. " Marketing, Product Differentiation and Competition in the Pharmaceutical Industry." Working Paper, MIT Department of Economics 1996
16. Kleit A N. " Using Advertising to Generate Information and Signals for Product Quality: Lessons for Biotechnology in Canada from Pharmaceutical Markets in the United States," Biotechnology and the Consumer 1998, 257-75. Mathios K A. in, edited by, Boston: Kluwer,
17. Knight Ridder News. " Drug Maker Merck reports 5% Increase in Profits." Tribune Business News 2001, July 21,
18. Leffler K. " Persuasion or Information? The Economics of Prescription Drug Advertising." Journal of Law and Economics 1981, 24:45-74.
19. Masson A, Rubin P. " Matching Prescription Drugs and Consumers: The Benefits of Direct Advertising." New England Journal of Medicine 1985, 313:513-15.
20. McDonald R, Siegel D. " The Value of Waiting to Invest." Quarterly Journal of Economics 1986, 101:707-28.
21. Merton R C. " An Intertemporal Capital Asset Pricing Model." Econometrica 1973, 41:867-87.
22. Morrill R, Cromartie J, Hart G. " Metropolitan, Urban, and Rural Commuting Areas: Toward a Better Descriptions of the United States Settlement System." Urban Geography 1999, 20:727-48.
23. Mukherjee D, Nissen S, Topol E. " Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors." Journal of American Medical Association 2001, 286:954-59.
24. National Institute for Health Care Management. " Prescription Drugs and Mass Media Advertising, 2000." Washington, DC: NIHCM Foundation, November 2001
25. " Pharmacia Has Setback for Parecoxib." Chemical Market Reporter July 2001, 8
26. Picone G, Wilson R, Chou S. " Analysis of Hospital Length of Stay and Discharge Destination Using Hazard Functions with Unmeasured Heterogeneity." Health Economics 2003, 12:1021-34.
27. Ridder G. " The Non-Parametric Identification of Generalized Accelerated Failure-Time Models." Review of Economic Studies 1990, 57:167-81.
28. Rizzo J. " Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Hypertensive Drugs." Journal of Law and Economics 1999, 42:89-116.
29. Rubin P. " Economics of Prescription Drug Advertising." Journal of Research in Pharmaceutical Economics 1991, 3(1):29-39.
30. Schumann M. " Top 100 Megabrands: Chevrolet Leads the Race Along Megabrand Road, but Marketers Hit 2001 Potholes." Advertising Age 2001, 72:1.
31. Telser L. " The Theory of Supply with Application to the Ethical Pharmaceutical Industry." Journal of Law and Economics 1975, 18:449-78.
32. Titman S. " Urban Land Prices Under Uncertainty." American Economic Review 1985, 75:505-14.
33. " Top Brands in Network Primetime-2000." Brandweek, April 23, 2001, 30.
34. Topol E. " Failing the Public Health-Rofecoxib, Merck and the FDA." New England Journal of Medicine 2004, 351:1707-09.
35. Zachry W M, S J, Coons, Ginsburg D B. " Patient Autonomy and the Regulation of Direct-to-Consumer Advertising." Clinical Therapy 2001, 23:2024-37.